Flossbach Von Storch AG Decreases Position in Thermo Fisher Scientific Inc. (TMO)

Flossbach Von Storch AG cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 41.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 21,608 shares of the medical research company’s stock after selling 15,402 shares during the period. Flossbach Von Storch AG’s holdings in Thermo Fisher Scientific were worth $5,274,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of TMO. Pitcairn Co. lifted its position in shares of Thermo Fisher Scientific by 1.3% in the second quarter. Pitcairn Co. now owns 16,871 shares of the medical research company’s stock valued at $3,495,000 after buying an additional 215 shares during the last quarter. Nvwm LLC lifted its position in shares of Thermo Fisher Scientific by 6.1% in the second quarter. Nvwm LLC now owns 4,231 shares of the medical research company’s stock valued at $877,000 after buying an additional 242 shares during the last quarter. Tiedemann Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 19.4% in the second quarter. Tiedemann Advisors LLC now owns 1,518 shares of the medical research company’s stock valued at $315,000 after buying an additional 247 shares during the last quarter. Chesapeake Wealth Management lifted its position in shares of Thermo Fisher Scientific by 6.0% in the second quarter. Chesapeake Wealth Management now owns 4,393 shares of the medical research company’s stock valued at $910,000 after buying an additional 249 shares during the last quarter. Finally, Middleton & Co Inc MA lifted its position in shares of Thermo Fisher Scientific by 2.3% in the third quarter. Middleton & Co Inc MA now owns 11,123 shares of the medical research company’s stock valued at $2,715,000 after buying an additional 250 shares during the last quarter. Institutional investors and hedge funds own 85.22% of the company’s stock.

TMO has been the subject of a number of recent analyst reports. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $274.00 price objective for the company in a research report on Monday, October 1st. ValuEngine raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, July 24th. UBS Group initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, October 9th. They issued a “buy” rating and a $295.00 price objective for the company. Citigroup raised their price objective on Thermo Fisher Scientific from $260.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, October 10th. Finally, Goldman Sachs Group cut Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research report on Monday, September 17th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $261.45.

NYSE:TMO opened at $243.45 on Friday. The company has a market cap of $95.91 billion, a P/E ratio of 25.65, a PEG ratio of 1.73 and a beta of 1.08. The company has a quick ratio of 1.27, a current ratio of 1.84 and a debt-to-equity ratio of 0.66. Thermo Fisher Scientific Inc. has a 1-year low of $181.51 and a 1-year high of $249.95.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 24th. The medical research company reported $2.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.55 by $0.07. The business had revenue of $5.92 billion during the quarter, compared to analysts’ expectations of $5.70 billion. Thermo Fisher Scientific had a return on equity of 16.49% and a net margin of 10.75%. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period last year, the firm posted $2.31 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 11.04 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, January 15th. Investors of record on Monday, December 17th will be issued a dividend of $0.17 per share. The ex-dividend date is Friday, December 14th. This represents a $0.68 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is currently 7.17%.

Thermo Fisher Scientific announced that its board has authorized a stock buyback program on Friday, September 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 2.1% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its stock is undervalued.

In related news, CEO Marc N. Casper sold 125,520 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $247.50, for a total transaction of $31,066,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.49% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first posted by WKRB News and is owned by of WKRB News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.wkrb13.com/2018/11/10/flossbach-von-storch-ag-decreases-position-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply